Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Buy" from Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has received a consensus rating of "Buy" from the ten research firms that are currently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $40.38.

Several research analysts recently weighed in on the company. Wedbush reaffirmed an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research note on Thursday, May 15th. BTIG Research assumed coverage on Oruka Therapeutics in a research note on Thursday, May 22nd. They set a "buy" rating for the company. Finally, Wall Street Zen raised Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 22nd.

Institutional Trading of Oruka Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in shares of Oruka Therapeutics in the fourth quarter worth approximately $343,000. Vanguard Group Inc. grew its stake in Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after purchasing an additional 1,572,853 shares in the last quarter. Squarepoint Ops LLC purchased a new position in Oruka Therapeutics in the fourth quarter valued at about $236,000. Millennium Management LLC purchased a new position in Oruka Therapeutics in the fourth quarter valued at about $588,000. Finally, Geode Capital Management LLC increased its holdings in Oruka Therapeutics by 2,348.6% in the fourth quarter. Geode Capital Management LLC now owns 342,418 shares of the company's stock worth $6,643,000 after buying an additional 328,434 shares during the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Stock Down 3.1%

ORKA stock traded down $0.45 during trading on Tuesday, reaching $14.25. 126,918 shares of the company's stock were exchanged, compared to its average volume of 234,505. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $31.13. The company's fifty day moving average price is $11.66 and its 200-day moving average price is $11.71. The firm has a market cap of $533.52 million, a PE ratio of -3.16 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.17. As a group, sell-side analysts expect that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.